Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Clinical Trials in Seattle, Washington
4 recruitingSeattle, Washington
Showing 1–4 of 4 trials
Recruiting
Phase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+12 more
National Cancer Institute (NCI)120 enrolled82 locationsNCT06649812
Recruiting
Phase 2
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+9 more
University of Washington27 enrolled1 locationNCT06784726
Recruiting
Phase 1
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+3 more
University of Washington56 enrolled1 locationNCT04231877
Recruiting
Phase 1Phase 2
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell LymphomaRecurrent Grade 3b Follicular LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Fred Hutchinson Cancer Center33 enrolled1 locationNCT07098364